Merck & Company, Inc. Press Releases

MRK 
$57.29
*  
1.20
2.05%
Get MRK Alerts
*Delayed - data as of Jun. 29, 2015  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

SIMPONI® (golimumab) Gains Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Non-Radiographic Axial Spondyloarthritis
5/26/2015 6:33:00 AM - PR Newswire
▼-3.52 % Price Change since this news event. The Volume Ratio is 1.86.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


MSD Receives Positive CHMP Opinion for Pembrolizumab for the Treatment of Advanced Melanoma
5/22/2015 7:12:00 AM - Business Wire
▼-4.68 % Price Change since this news event. The Volume Ratio is 1.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
5/22/2015 7:12:00 AM - Business Wire
▼-4.68 % Price Change since this news event. The Volume Ratio is 1.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Erin Energy Announces Production Rate from the Oyo Field
5/18/2015 8:00:00 AM - Business Wire


Merck to Present at the UBS Global Healthcare Conference
5/18/2015 8:00:00 AM - Business Wire
▼-5.54 % Price Change since this news event. The Volume Ratio is 0.88.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented
5/13/2015 5:00:00 PM - Business Wire
▼-3.31 % Price Change since this news event. The Volume Ratio is 0.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Merck Announces First-Quarter 2015 Financial Results
4/28/2015 7:00:00 AM - Business Wire